



15<sup>th</sup> January 2019

**Notice: License Agreement Concluded with Aligos Therapeutics, Inc.**

Luxiana Biotech Co., Ltd. (Osaka, President & CEO Hideaki Sato) and Aligos Therapeutics, Inc. (South San Francisco, CEO Lawrence Blatt) have concluded a worldwide re-license right agreement of the innovative modified nucleic acid technology targeting multiple genes in specific diseases. By this agreement Aligos Therapeutics would discover oligonucleotide therapeutics against multiple gene targets (targets are not disclosed) in specific diseases by using the modified nucleic acid technology.

Based on the agreement, Luxna Biotech would receive an upfront fee (technical access fee) from Aligos Therapeutics (the amount is not disclosed). In future Luxna Biotech would be paid to the milestone fee according to the progress of development and royalties according to the sales amount after productization.

We believe this agreement would be the first step that the nucleic acid technologies, invented by Academia, would be widely promoted overseas to discover oligonucleotide therapeutics.

About Aligos Therapeutics, Inc.

Aligos Therapeutics is a biotech that is based in South San Francisco and promotes the development of drugs specializing in diseases of the liver and viral diseases.

About Luxna Biotech Co., Ltd.

Luxna Biotech is a biotech to be founded to support patients who are suffering from diseases and to create oligonucleotide therapeutics by installing technologies that promote the use of oligonucleotide therapeutics in the clinical setting.

**Contact Us**

Luxna Biotech Co., Ltd.

E-mail: [info@luxnabiotech.co.jp](mailto:info@luxnabiotech.co.jp)

HP : <https://luxnabiotech.co.jp/>